Interferon-beta increases plasma ceramides of specific chain length in multiple sclerosis patients, unlike fingolimod or natalizumab
Fingolimod is used for the treatment of multiple sclerosis (MS) and targets receptors for the bioactive sphingolipid sphingosine-1-phosphate. Whether fingolimod or other MS therapies conversely affect plasma concentrations of sphingolipids has, however, not yet been analyzed. Herein, we quantified 1...
Kaydedildi:
| Asıl Yazarlar: | , , , , , , , , |
|---|---|
| Materyal Türü: | Artigo |
| Dil: | Inglês |
| Baskı/Yayın Bilgisi: |
Frontiers Media S.A.
2016-11-01
|
| Seri Bilgileri: | Frontiers in Pharmacology |
| Konular: | |
| Online Erişim: | http://journal.frontiersin.org/Journal/10.3389/fphar.2016.00412/full |
| Etiketler: |
Etiket eklenmemiş, İlk siz ekleyin!
|